Nurix治疗工具打破了对收入的预期,但面临内部销售和分析师的不同意见。 Nurix Therapeutics beat earnings expectations but faces insider sales and mixed analyst views.

Nurix Therapeutics 报告的收益和收入超出了分析师的预期，尽管该公司的财务指标仍然为负值。 Nurix Therapeutics reported earnings and revenue that beat analysts' expectations, though the company still has negative financial metrics. 在收入报告之后,股票开张9.26美元。 The stock opened at $9.26 following the earnings report. 内部人最近出售股票,有些分析家更新股票,另一些则降低价格目标。 Insiders have sold shares recently, and while some analysts upgraded the stock, others lowered price targets. Nurix是一家生物制药公司,开发治疗癌症和炎症的疗法。 Nurix is a biopharmaceutical company developing therapies for cancer and inflammatory conditions.